Effects of GLP-1-based Therapies on Gut Motility
Author Information
Author(s): Jalleh Ryan, Marathe Chinmay S, Rayner Christopher K, Jones Karen L, Umapathysivam Mahesh M, Wu Tongzhi, Quast Daniel R, Plummer Mark P, Nauck Michael A, Horowitz Michael
Primary Institution: Royal Adelaide Hospital, Adelaide, Australia
Hypothesis
How do GLP-1-based therapies affect gastric, biliary, and intestinal motility?
Conclusion
GLP-1-based therapies slow gastric emptying and have complex effects on gastrointestinal motility, which can influence postprandial glucose levels and energy intake.
Supporting Evidence
- GLP-1-based therapies improve glycemic control and promote weight loss.
- These therapies can slow gastric emptying, which may lower post-meal blood sugar spikes.
- Clinical trials show that GLP-1 receptor agonists have cardiovascular and renal protective effects.
- Slower gastric emptying can lead to reduced energy intake and increased feelings of fullness.
Takeaway
GLP-1 medications help control blood sugar and weight by slowing down how fast food leaves the stomach, which can also affect how hungry you feel.
Methodology
The review summarizes existing studies on the effects of GLP-1-based therapies on gastrointestinal motility.
Limitations
Many studies used suboptimal methods to measure gastric emptying.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website